8-K: Zomedica Reports Record Q4, Full-Year 2025 Revenue Growth

Zomedica Corp. announced record fourth-quarter revenue of $10.5 million and full-year 2025 revenue of $32.0 million, marking 17% annual growth and its 20th consecutive quarter of year-over-year revenue increase.

Summary

• Record fourth-quarter 2025 revenue reached $10.5 million, a 33% increase compared to the fourth quarter of 2024.
• Full-year 2025 revenue was $32.0 million, an increase of $4.7 million or 17% from $27.3 million in 2024, marking the 20th straight quarter of year-over-year revenue growth.
• Gross margin for the full year 2025 was 68%, with the fourth quarter achieving 69%.
• Operating expenses, excluding impairment charges, decreased by $3.9 million or 7% from the prior year to $50.2 million.
• Cash burn for the year was $18.1 million, including a significantly reduced $1.1 million in the fourth quarter, both representing the lowest in the company's history since commercialization.
• The new Development Services business segment generated $3.1 million in revenue in 2025, primarily in the second half of the year.
• International sales grew an impressive 18% in 2025.
• Net loss for the year ended December 31, 2025, was $81.9 million, which includes a non-cash impairment charge of $55.8 million.
• Adjusted Non-GAAP EBITDA loss improved to $17.1 million for 2025, compared to a loss of $20.2 million for 2024.
• Zomedica maintained $53.3 million in cash, cash equivalents, and available-for-sale securities as of December 31, 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report due to strong revenue growth, improved operational efficiency, and reduced cash burn, despite a significant non-cash impairment charge impacting net loss.

Positives

• Achieved record fourth-quarter revenue of $10.5 million, a 33% increase over Q4 2024.
• Delivered record full-year revenue of $32.0 million, representing 17% annual growth and the 20th consecutive quarter of year-over-year revenue growth.
• Maintained strong gross margins at 68% for the full year and 69% for Q4 2025.
• Operating expenses (excluding impairment) decreased by $3.9 million, or 7%, from the prior year, reflecting disciplined cost management.
• Cash burn for the year was $18.1 million, with Q4 cash burn at $1.1 million, both the lowest since commercialization, indicating greater efficiency.
• The new Development Services business segment successfully generated $3.1 million in revenue, primarily in the second half of 2025, opening new revenue opportunities.
• International sales grew an impressive 18%, driven by organic growth and new distributor partners.
• Adjusted Non-GAAP EBITDA loss improved to $17.1 million in 2025 from $20.2 million in 2024.
• Maintained strong liquidity with $53.3 million in cash, cash equivalents, and available-for-sale securities as of December 31, 2025.

Negatives

• Net loss for the year ended December 31, 2025, was $81.9 million, a significant increase from the $47.0 million net loss in 2024.
• The net loss includes a substantial non-cash impairment charge of $55.8 million, triggered by a decline in the company's market capitalization.
• Non-GAAP EBITDA loss for 2025 was $74.1 million, compared to a loss of $40.7 million in 2024, with both periods including impairment expense.
• Capital revenues, comprised of PulseVet and VETGuardian product sales, were $9.3 million, down 2% over 2024 revenues.

Risks

• Uncertainty as to whether the new Development Services business segment will continue to generate revenue.
• Uncertainty as to whether strategies and business plans will yield the expected benefits.
• Uncertainty as to the timing and results of development work and verification and validation studies.
• Uncertainty as to the timing and results of commercialization efforts, including international efforts, as well as the cost of commercialization efforts.
• Uncertainty as to the ability to realize the anticipated growth opportunities from acquisitions.
• Uncertainty as to the ability to supply products in response to customer demand.
• Supply chain risks associated with tariff changes.
• Uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital.
• The ability to identify and develop and achieve commercial success for new products and technologies.
• Veterinary acceptance of products and purchase of consumables following adoption of capital equipment.
• Competition from related products.
• The level of expenditures necessary to maintain and improve the quality of products and services.
• Changes in technology and changes in laws and regulations.
• The ability to secure and maintain strategic relationships.
• Performance by strategic partners of their obligations under commercial agreements, including product manufacturing obligations.
• Risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of products, and intellectual property protection.

Future Outlook

Zomedica aims to accelerate global adoption of its innovative portfolio and continue driving toward cash flow breakeven and profitability in 2026, building on the momentum generated in 2025 to deliver long-term value. The company remains optimistic about generating material revenue from its new Development Services segment and continuing to drive operating leverage.

Management Comments

• "Delivering 17% growth and achieving record year-over-year revenue for the 20th straight quarter demonstrates the consistency and resilience of our business." Larry Heaton, Chief Executive Officer of Zomedica.
• "Crossing $10 million in quarterly sales, up from the prior record of $8 million set in the third quarter, marks an important milestone for our company and reinforces our belief that our long-term strategy is working." Larry Heaton, Chief Executive Officer of Zomedica.
• "Driven by strong and sustained demand for our PulseVet and Assisi therapeutic device products, accelerating adoption of our diagnostic offerings, particularly the expanding TRUFORMA platform, and continued momentum in our newly introduced Development Services segment, we delivered the strongest quarter in our company’s history as measured by revenue and adoption metrics." Larry Heaton, Chief Executive Officer of Zomedica.
• "2025 was a pivotal and highly productive year for Zomedica as we continued to execute on our strategy to build a leading equine and companion animal healthcare company." Larry Heaton, Chief Executive Officer of Zomedica.
• "Our new Development Services business segment, which generated revenue of $3.1 million (primarily in the second half of the year), has opened new revenue opportunities by leveraging our development, engineering, and contract manufacturing expertise. We remain optimistic about our ability to generate material revenue from this new segment and continue to drive operating leverage." Larry Heaton, Chief Executive Officer of Zomedica.
• "As we enter 2026, our priorities remain clear: accelerate global adoption of our innovative portfolio and continue driving toward cash flow breakeven and profitability. We believe Zomedica is well positioned to build on the momentum generated in 2025 and to deliver long-term value." Larry Heaton, Chief Executive Officer of Zomedica.

Industry Context

StockSavvy.ai notes that Zomedica's consistent revenue growth and expansion into development services align with broader trends in the animal health industry, where innovation in diagnostics and therapeutics, coupled with strategic diversification, is key for market leadership. The focus on both equine and companion animals positions Zomedica to capture a significant share of the over $2 billion U.S. total addressable market.

Comparison to Industry Standards

• Zomedica's 17% annual revenue growth in 2025 is robust, especially when compared to the average growth rates of established animal health companies, which often range from 5-10%. For instance, IDEXX Laboratories (IDXX) typically reports mid-to-high single-digit revenue growth, while Zoetis (ZTS) also generally sees similar growth. Zomedica's growth suggests strong market penetration and product acceptance for its specialized offerings like PulseVet and TRUFORMA.
• The 68% gross margin is competitive within the animal health sector. Companies like Heska Corporation (HSKA, prior to acquisition) and other diagnostic providers often aim for gross margins in the 60-75% range, indicating Zomedica's operational efficiency in product manufacturing and sales.
• The significant non-cash impairment charge of $55.8 million, while impacting net loss, is a common occurrence for companies with recent acquisitions or those experiencing market capitalization declines, reflecting accounting adjustments rather than operational cash flow issues. This is similar to how larger pharmaceutical or medical device companies might record impairment charges on acquired intangible assets if market conditions change.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value through continued revenue growth, improved profitability, and reduced cash burn. The non-cash impairment charge, while impacting reported net loss, does not affect cash flow directly.
• Employees: Continued investment in internal capabilities and increased headcount in selling and marketing suggest stable to growing employment opportunities.
• Customers (Veterinarians): Enhanced product offerings and expanded reach, including international sales, indicate continued access to innovative therapeutic and diagnostic solutions.
• Suppliers: Continued demand for products and consumables suggests stable business for suppliers.

Next Steps

• Accelerate global adoption of the innovative product portfolio.
• Continue driving toward cash flow breakeven and profitability.
• Build on momentum generated in 2025 to deliver long-term value.
• Host the Fourth Friday at Four Webinar on March 27, 2026, to review full-year financial performance.

Key Dates

Recommendation

While Zomedica demonstrated strong revenue growth, improved operational efficiency, and reduced cash burn, the substantial net loss driven by a non-cash impairment charge and continued adjusted EBITDA loss suggest the company is still in a growth phase with profitability yet to be consistently achieved. The positive operational trends are encouraging, but the overall financial picture warrants a "hold" recommendation as investors await sustained profitability and further reduction in losses before a stronger buy signal. The stock is on OTCQB, which also adds a layer of caution.

Keywords

Zomedica, ZOMDF, animal health, veterinary diagnostics, veterinary therapeutics, PulseVet, Assisi Loop, TRUFORMA, financial results, revenue growth, gross margin, cash burn, Development Services, Q4 2025, full year 2025